Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lisparin (lisuride)
- Development stage
- Phase 2
- Lead developer
- Axxonis Pharma
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Lisparin is a branded formulation of lisuride, a small molecule dopamine receptor agonist, developed by Axxonis Pharma for the treatment of advanced, idiopathic Parkinson's disease. It is specifically designed for continuous subcutaneous infusion via a portable minipump device, a delivery method intended to provide stable plasma concentrations and continuous dopaminergic stimulation. This approach aims to mitigate the motor fluctuations and 'OFF' periods commonly experienced by patients with advanced disease who have become refractory to conventional oral therapies. Lisuride acts as a potent agonist at D2, D3, and D4 dopamine receptors and also interacts with various serotonin and adrenergic receptor subtypes, including acting as a 5-HT1A agonist and 5-HT2A/2C antagonist. The Lisparin program has been evaluated in Phase II/III clinical trials to establish its efficacy and safety in smoothing out motor responses in advanced Parkinson's patients.
- Brand names
- Lisparin
- Other names
- subcutaneous lisuride
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on Lisparin (lisuride).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lisparin (lisuride).